[Comment] A step forward in the treatment of relapsed or refractory follicular lymphoma

Follicular lymphoma remains an incurable malignancy characterised by successive relapses. Despite favourable initial responses to front-line therapy, most patients eventually relapse, and lymphoma or treatment-related complications remain the leading cause of death.1 Accumulating evidence shows that the duration of response shortens with each subsequent line of therapy, resulting in progressively reduced progression-free survival and overall survival after each line of treatment.2,3